Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01017263 · ClinicalTrials.gov registry record · Phase 4
Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity
A Phase 4 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT01017263 is a Phase 4 study that was terminated before completion, run by Duke University. The registered enrollment target is 14 participants.
The verdict
NCT01017263, a Phase 4 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study to assess the effects of chronic administration of Vyvanse (lis-dexamphetamine) on glucose metabolism in a sample of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) who also have glucose intolerance and are obese.
Interventions
- DRUG Lis-dexamphetamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2009-12 |
| Est. Completion | 2012-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01017263
The ClinicalTrials.gov registry entry for NCT01017263 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lis-dexamphetamine is the first listed.
NCT01017263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01017263 about?
NCT01017263 is a clinical study titled "Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity". The purpose of this study to assess the effects of chronic administration of Vyvanse (lis-dexamphetamine) on glucose metabolism in a sample of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) who also have glucose intolerance and are obese.
What is the current status of trial NCT01017263?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2009-12. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01017263?
The interventions under investigation include: Lis-dexamphetamine (DRUG).
Who is sponsoring clinical trial NCT01017263?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.